troglitazone has been researched along with Diabetic Nephropathies in 13 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Diabetic Nephropathies: KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Troglitazone, a newly developed thiazolidinedione derivative, has been shown to ameliorate microalbuminuria in diabetic animal model and in human diabetic nephropathy in short-term studies." | 9.09 | Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in Type 2 diabetic patients with microalbuminuria or macroalbuminuria. ( Ebihara, L; Koide, H; Nakamura, T; Sekizuka, K; Shimada, N; Suzuki, S; Ushiyama, C, 2001) |
| "Troglitazone ameliorated microalbuminuria in diabetic nephropathy." | 9.08 | Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. ( Arai, K; Hori, M; Imano, E; Kajimoto, Y; Kanda, T; Motomura, M; Nakatani, Y; Nishida, T; Yamasaki, Y, 1998) |
| "Troglitazone, a newly developed thiazolidinedione derivative, has been shown to ameliorate microalbuminuria in diabetic animal model and in human diabetic nephropathy in short-term studies." | 5.09 | Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in Type 2 diabetic patients with microalbuminuria or macroalbuminuria. ( Ebihara, L; Koide, H; Nakamura, T; Sekizuka, K; Shimada, N; Suzuki, S; Ushiyama, C, 2001) |
| "Troglitazone ameliorated microalbuminuria in diabetic nephropathy." | 5.08 | Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. ( Arai, K; Hori, M; Imano, E; Kajimoto, Y; Kanda, T; Motomura, M; Nakatani, Y; Nishida, T; Yamasaki, Y, 1998) |
| " Recent studies demonstrated that hypoglycemic agents improving insulin resistance such as metformin and troglitazone reduce blood pressure." | 4.79 | [Treatment of hypertension associated with diabetes mellitus]. ( Katayama, S, 1997) |
| "Thus, diabetic nephropathy is currently the number one cause of end-stage renal disease in the Western world." | 2.43 | Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. ( Bakris, GL; Sarafidis, PA, 2006) |
| "However, regulation of Angptl8 in human type 2 diabetes mellitus (T2DM) and renal dysfunction has not been determined." | 1.40 | Circulating angiopoietin-like protein 8 is independently associated with fasting plasma glucose and type 2 diabetes mellitus. ( Bachmann, A; Blüher, M; Ebert, T; Fasshauer, M; Hoffmann, A; Kralisch, S; Kratzsch, J; Lössner, U; Stumvoll, M; Tönjes, A, 2014) |
| "Troglitazone was less effective in controlling serum cholesterol and neuropathy." | 1.31 | Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats. ( Kakimoto, K; Shibata, T; Takeuchi, S; Wakitani, K; Yokota, S; Yonemori, F, 2000) |
| "Diabetic nephropathy is characterized functionally by glomerular hyperfiltration and albuminuria and histologically by the expansion of glomerular mesangium." | 1.31 | Cellular mechanisms in the development and progression of diabetic nephropathy: activation of the DAG-PKC-ERK pathway. ( Haneda, M; Kikkawa, R; Koya, D, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 10 (76.92) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ebert, T | 1 |
| Kralisch, S | 1 |
| Hoffmann, A | 1 |
| Bachmann, A | 1 |
| Lössner, U | 1 |
| Kratzsch, J | 1 |
| Blüher, M | 1 |
| Stumvoll, M | 1 |
| Tönjes, A | 1 |
| Fasshauer, M | 1 |
| Inukai, T | 1 |
| Takanashi, K | 1 |
| Tayama, K | 1 |
| Aso, Y | 1 |
| Takemura, Y | 1 |
| Yotsumoto, T | 1 |
| Naitoh, T | 1 |
| Kanaki, T | 1 |
| Matsuda, M | 1 |
| Tsuruzoe, N | 1 |
| Ogawa, M | 1 |
| Hirawa, N | 1 |
| Tsuchida, T | 1 |
| Eguchi, N | 1 |
| Kawabata, Y | 1 |
| Numabe, A | 1 |
| Negoro, H | 1 |
| Hakamada-Taguchi, R | 1 |
| Seiki, K | 1 |
| Umemura, S | 1 |
| Urade, Y | 1 |
| Uehara, Y | 1 |
| Sarafidis, PA | 1 |
| Bakris, GL | 1 |
| Katayama, S | 1 |
| Imano, E | 1 |
| Kanda, T | 1 |
| Nakatani, Y | 1 |
| Nishida, T | 1 |
| Arai, K | 1 |
| Motomura, M | 1 |
| Kajimoto, Y | 1 |
| Yamasaki, Y | 1 |
| Hori, M | 1 |
| Shibata, T | 1 |
| Takeuchi, S | 1 |
| Yokota, S | 1 |
| Kakimoto, K | 1 |
| Yonemori, F | 1 |
| Wakitani, K | 1 |
| McCarthy, KJ | 1 |
| Routh, RE | 1 |
| Shaw, W | 1 |
| Walsh, K | 1 |
| Welbourne, TC | 1 |
| Johnson, JH | 1 |
| Nicholas, SB | 1 |
| Kawano, Y | 1 |
| Wakino, S | 1 |
| Collins, AR | 1 |
| Hsueh, WA | 1 |
| Nakamura, T | 1 |
| Ushiyama, C | 1 |
| Suzuki, S | 1 |
| Shimada, N | 1 |
| Sekizuka, K | 1 |
| Ebihara, L | 1 |
| Koide, H | 1 |
| Haneda, M | 1 |
| Koya, D | 1 |
| Kikkawa, R | 1 |
| Yamashita, H | 1 |
| Nagai, Y | 1 |
| Takamura, T | 1 |
| Nohara, E | 1 |
| Kobayashi, K | 1 |
2 reviews available for troglitazone and Diabetic Nephropathies
| Article | Year |
|---|---|
Protection of the kidney by thiazolidinediones: an assessment from bench to bedside.
Topics: Albuminuria; Animals; Blood Pressure; Chromans; Diabetes Mellitus, Type 2; Diabetic Nephropathies; E | 2006 |
[Treatment of hypertension associated with diabetes mellitus].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cerebrovascular Disorders; Chroma | 1997 |
3 trials available for troglitazone and Diabetic Nephropathies
| Article | Year |
|---|---|
High glucose concentrations abolish the superoxide dismutase response of leukocytes to ascorbic acid or troglitazone in type 2 diabetes mellitus.
Topics: Aged; Albuminuria; Antioxidants; Ascorbic Acid; Chromans; Diabetes Mellitus, Type 2; Diabetic Nephro | 2002 |
Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy.
Topics: Aged; Albuminuria; Blood Glucose; Blood Pressure; C-Peptide; Cholesterol; Cholesterol, HDL; Chromans | 1998 |
Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in Type 2 diabetic patients with microalbuminuria or macroalbuminuria.
Topics: Albuminuria; Animals; Blood Pressure; Chromans; Collagen; Creatinine; Diabetes Mellitus, Type 2; Dia | 2001 |
8 other studies available for troglitazone and Diabetic Nephropathies
| Article | Year |
|---|---|
Circulating angiopoietin-like protein 8 is independently associated with fasting plasma glucose and type 2 diabetes mellitus.
Topics: 3T3-L1 Cells; Adipocytes; Angiopoietin-Like Protein 8; Angiopoietin-like Proteins; Animals; Blood Gl | 2014 |
A novel peroxisome proliferator-activated receptor (PPAR)gamma agonist, NIP-222, reduces urinary albumin excretion in streptozotocin-diabetic mice independent of PPARgamma activation.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Glucose; Blood Pressure; Body | 2003 |
Urinary excretions of lipocalin-type prostaglandin D2 synthase predict the development of proteinuria and renal injury in OLETF rats.
Topics: Animals; Chromans; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Hypoglycemic Agents; Immunoenz | 2006 |
Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats.
Topics: Absorptiometry, Photon; Animals; Body Weight; Bone Density; Bone Diseases, Metabolic; Cataract; Chro | 2000 |
Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion.
Topics: Animals; Basement Membrane; Body Weight; Chondroitin Sulfate Proteoglycans; Chromans; Diabetes Melli | 2000 |
Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells.
Topics: Animals; Cell Nucleus; Cells, Cultured; Chromans; Cytoplasm; Diabetes Mellitus, Experimental; Diabet | 2001 |
Cellular mechanisms in the development and progression of diabetic nephropathy: activation of the DAG-PKC-ERK pathway.
Topics: Animals; Chromans; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diacylglycerol Kinase; Disease | 2001 |
Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin-induced diabetic spontaneous hypertensive rat.
Topics: Albuminuria; Animals; Basement Membrane; Blood Glucose; Blood Pressure; Body Weight; Chromans; Creat | 2002 |